当前位置： SCI文献检索 > ANTIVIRAL THERAPY期刊下所有文献 > Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy.

Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy.

Abstract：

BACKGROUND:This study aimed to examine the evolution of genotypic drug resistance prevalence in treatment-failing patients in the multicentre, Italian, Antiretroviral Resistance Cohort Analysis (ARCA). METHODS:Patients with a drug resistance genotype test performed between 1999 and 2006 at failure of a combination antiretroviral therapy and with complete treatment history were selected. The prevalence of resistance was measured overall, per calendar year, per drug class and per treatment line at failure. RESULTS:The overall resistance prevalence was 81%. Resistance to nucleoside reverse transcriptase inhibitors (NRTIs) declined after 2002 (68% in 2006; chi(2) for trend P=0.004); resistance to non-NRTIs (NNRTIs) stabilized after 2004; and resistance to protease inhibitors (PIs) declined after 2001 (43% in 2006; P=0.004). In first-line failures, NRTI resistance decreased after 2002 (P=0.006), NNRTI resistance decreased after 2003 (P=0.001) and PI resistance decreased after 2001 (P<0.001). Independent predictors of resistance to any class were HIV type-1 transmission by heterosexual contacts as compared with injecting drug use, a higher number of experienced regimens, prior history of suboptimal therapy, higher viral load and CD4+ T-cell counts, more recent calendar year and viral subtype B carriage, whereas the use of PI-based versus NNRTI-based regimens at failure was associated with a reduced risk of resistance. There was an increase of type-1 thymidine analogue and of protease mutations L33F, I47A/V, I50V and I54L/M, whereas L90M decreased over calendar years. CONCLUSIONS:During more recent years, emerging drug resistance has decreased, particularly in first-line failures. The prevalence continues to be high in multiregimen-failing patients.

journal_name

Antivir Ther

journal_title

Antiviral therapy

authors

Di Giambenedetto S,Zazzi M,Corsi P,Gonnelli A,Di Pietro M,Giacometti A,Almi P,Trezzi M,Boeri E,Gianotti N,Menzo S,Del Gobbo R,Francisci D,Nerli A,Galli L,De Luca A,Antiretroviral Resistance Cohort Analysis Study Group.

subject

Has Abstract

pub_date

2009-01-01 00:00:00

pages

359-69

issue

3

eissn

1359-6535

issn

2040-2058

journal_volume

14

pub_type

杂志文章,多中心研究

相关文献

ANTIVIRAL THERAPY文献大全
  • Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?

    abstract：BACKGROUND:Increasing efavirenz (EFV) dose from 600 mg to 800 mg daily has been suggested with concomitant rifampicin (RFN), as induction of cytochrome P450 isoenzymes may reduce EFV plasma concentrations. METHODS:Individuals from the CIPRA-South Africa cohort taking EFV-based antiretroviral therapy with concomitant t...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章

    doi：10.3851/IMP1780

    authors： Orrell C,Cohen K,Conradie F,Zeinecker J,Ive P,Sanne I,Wood R

    更新日期：2011-01-01 00:00:00

  • Treatment of pegylated interferon-α2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation.

    abstract：BACKGROUND:Acute exacerbation (AE) in chronic hepatitis B (CHB) is usually followed by a spontaneous decline in HBV DNA levels. The subsequent treatment is controversial. In this study, we evaluated the efficacy and safety of pegylated interferon-α2a (PEG-IFN-α2a) for such CHB patients. METHODS:A total of 74 hepatitis...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2832

    authors： Cai Q,Chen F,Shao X,Zhang X,Zhao Z,Gao Z

    更新日期：2015-01-01 00:00:00

  • Prevalence of transmitted HIV-1 drug resistance among young adults attending HIV counselling and testing clinics in Kigali, Rwanda.

    abstract：BACKGROUND:Scaling-up antiretroviral therapy (ART) in resource-limited settings has raised concerns of emerging HIV drug resistance (DR) and its transmission to newly infected individuals. To assess the prevalence of transmitted drug resistance (TDR) in recently HIV-infected individuals, a WHO TDR threshold survey was ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2999

    authors： Mutagoma M,Ndahimana Jd,Kayirangwa E,Dahourou AG,Balisanga H,DeVos JR,McAlister D,Yang C,Bertagnolio S,Riedel DJ,Nsanzimana S

    更新日期：2016-01-01 00:00:00

  • Tenofovir disoproxil fumarate monotherapy is superior to entecavir-adefovir combination therapy in patients with suboptimal response to lamivudine-adefovir therapy for nucleoside-resistant HBV: a 96-week prospective multicentre trial.

    abstract：BACKGROUND:A complete virological response is closely related to the long-term outcome of patients with chronic hepatitis B and prevention of emerging HBV mutations. We aimed to evaluate the efficacy of tenofovir disoproxil fumarate (TDF) monotherapy compared to entecavir-adefovir dipivoxil (ETV-ADV) combination therap...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.3851/IMP3169

    authors： Lee SH,Cheon GJ,Kim HS,Kim SG,Kim YS,Jeong SW,Jang JY,Kim BS,Jun BG,Don Kim Y,Jun DW,Sohn JH,Kim TY,Lee BS

    更新日期：2018-01-01 00:00:00

  • Characterization of HCV resistance from a 3-day monotherapy study of voxilaprevir, a novel pangenotypic NS3/4A protease inhibitor.

    abstract：BACKGROUND:Voxilaprevir (VOX; GS-9857) is a pangenotypic HCV NS3/4A protease inhibitor (PI) with potent antiviral activity against HCV genotypes (GTs) 1-6 and improved coverage of GT1 NS3 resistance-associated substitutions (RAS) associated with other HCV PIs. In a 3-day Phase Ib monotherapy study in patients infected ...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.3851/IMP3202

    authors： Lawitz E,Yang JC,Stamm LM,Taylor JG,Cheng G,Brainard DM,Miller MD,Mo H,Dvory-Sobol H

    更新日期：2018-01-01 00:00:00

  • Virological response in multidrug-experienced HIV-1-infected subjects failing highly active combination regimens after shifting from lamivudine to didanosine.

    abstract：:The aim of this study (the RESCUE trial) was to verify the effect of a shift from a lamivudine-containing to a didanosine-containing regimen on viral replication in HIV-1-infected subjects who had experienced prior treatment failure. Sixteen patients (didanosine-experienced in 14/16 cases) were consecutively enrolled:...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Rusconi S,La Seta Catamancio S,Citterio P,Bulgheroni E,Kurtagic S,Galazzi M,Croce F,Moroni M,Galli M

    更新日期：2001-03-01 00:00:00

  • Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients.

    abstract：BACKGROUND:Mutations in the genome of HIV conferring drug resistance are a major reason for the failure of antiretroviral therapy, but they often compromise viral fitness. Protease (PR) cleavage site (CS) mutations could compensate for impaired replication capacity of drug-resistant viruses. PATIENTS AND METHODS:We an...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Verheyen J,Litau E,Sing T,Däumer M,Balduin M,Oette M,Fätkenheuer G,Rockstroh JK,Schuldenzucker U,Hoffmann D,Pfister H,Kaiser R

    更新日期：2006-01-01 00:00:00

  • Expression of pregnane-X-receptor transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA.

    abstract：:P-glycoprotein (P-gp) limits bioavailability and accumulation of HIV protease inhibitors (PIs). PIs are ligands for the pregnane-X-receptor (PXR), which regulates P-gp expression. This occurs when ligands activate the receptor, initiating binding to response elements in the MDR1 promoter. PXR also activates cytochrome...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Owen A,Chandler B,Back DJ,Khoo SH

    更新日期：2004-10-01 00:00:00

  • The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir.

    abstract：:Boceprevir and telaprevir are peptidomimetic serine protease inhibitors that have been recently approved for the treatment of HCV chronic infection. The addition of these drugs to the prior standard of care, pegylated interferon and ribavirin, improves sustained virological response rates for treatment-naive and treat...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：10.3851/IMP2424

    authors： Marks KM,Jacobson IM

    更新日期：2012-01-01 00:00:00

  • Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy.

    abstract：BACKGROUND:Longitudinal assessment of liver fibrosis with transient elastometry (TE) in patients with chronic viral hepatitis is becoming routine clinical practice in many clinics, as this procedure is non-invasive, easy to perform and relatively inexpensive, allowing early detection of cirrhosis. Herein, we examine th...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP1630

    authors： Tuma P,Medrano J,Resino S,Vispo E,Madejón A,Sánchez-Piedra C,Rivas P,Labarga P,Martín-Carbonero L,Barreiro P,Soriano V

    更新日期：2010-01-01 00:00:00

  • Skin reactions in patients with influenza treated with oseltamivir: a retrospective cohort study.

    abstract：:Oseltamivir phosphate is an FDA-approved treatment for influenza that has been available for prescription use in the USA since 1999. The present report describes findings from a post-marketing safety study of skin reactions associated with oseltamivir use. All patients in the claims-derived Ingenix Research Database w...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Nordstrom BL,Oh K,Sacks ST,L'Italien GJ

    更新日期：2004-04-01 00:00:00

  • Plasma lopinavir concentrations predict virological failure in a cohort of South African children initiating a protease-inhibitor-based regimen.

    abstract：BACKGROUND:Poor adherence to antiretroviral therapy contributes to pharmacokinetic variability and is the major determinant of virological failure. However, measuring treatment adherence is difficult, especially in children. We investigated the relationship between plasma lopinavir concentrations, pretreatment characte...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2749

    authors： Moholisa RR,Schomaker M,Kuhn L,Meredith S,Wiesner L,Coovadia A,Strehlau R,Martens L,Abrams EJ,Maartens G,McIlleron H

    更新日期：2014-01-01 00:00:00

  • The enrichment of HBV immune-escape mutations during nucleoside/nucleotide analogue therapy.

    abstract：BACKGROUND:Drug-resistant HBV mutants frequently arise during nucleoside/nucleotide analogue (NA) therapy, while the resistance mutations on polymerase also have consequent changes in the S protein. The enrichment of immune-escape mutations was negatively correlated with hepatitis B surface antigen (HBsAg) clearance un...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3156

    authors： Shan M,Shen Z,Sun H,Zheng J,Zhang M

    更新日期：2017-01-01 00:00:00

  • MicroRNAs: role and therapeutic targets in viral hepatitis.

    abstract：:MicroRNAs regulate gene expression by binding to the 3'-untranslated region (UTR) of target messenger RNAs (mRNAs). The importance of microRNAs has been shown for several liver diseases, for example, viral hepatitis. MicroRNA-122 is highly abundant in the liver and is involved in the regulation of lipid metabolism. Mi...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：10.3851/IMP2766

    authors： van der Ree MH,de Bruijne J,Kootstra NA,Jansen PL,Reesink HW

    更新日期：2014-01-01 00:00:00

  • The prevalence of darunavir-associated mutations in HIV-1-infected children in the UK.

    abstract：BACKGROUND:We examined the prevalence of ritonavir-boosted darunavir (DRV) resistance-associated mutations (RAMs) in HIV-infected children in the UK to determine the drug's potential clinical utility as a first-line or second-line protease inhibitor (PI). METHODS:The prevalence of DRV RAMs, identified from IAS 2010 an...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2015

    authors： Donegan KL,Walker AS,Dunn D,Judd A,Pillay D,Menson E,Lyall H,Tudor-Williams G,Gibb DM,Collaborative HIV Paediatric Study.,UK HIV Drug Resistance Database.

    更新日期：2012-01-01 00:00:00

  • 3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir.

    abstract：BACKGROUND:Few data are available about efficacy and durability of simplification from multi-tablet antiretroviral regimens to co-formulated efavirenz (EFV)/emtricitabine (FTC)/tenofovir (TDF) versus rilpivirine (RPV)/FTC/TDF in virologically suppressed HIV-1-infected patients. METHODS:We retrospectively analysed HIV-...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,多中心研究

    doi：10.3851/IMP3188

    authors： Gagliardini R,Bandera A,Zaccarelli M,Sterrantino G,Latini A,D'Avino A,Lapadula G,Antinori A,Cauda R,De Luca A,Gori A,Di Giambenedetto S,Fabbiani M

    更新日期：2018-01-01 00:00:00

  • In vitro inhibition of HIV-1 by Met-SDF-1beta alone or in combination with antiretroviral drugs.

    abstract：:Compounds that can block the CXCR4 chemokine receptor are a promising new class of antiretroviral agents. In these experiments we studied the effect of a modified form of the native stromal cell-derived factor-1 (SDF-1), Met-SDF-1beta. The in vitro susceptibility of two different CXCR4-tropic HIV-1 strains was determi...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Rusconi S,Merrill DP,La Seta Catamancio S,Citterio P,Bulgheroni E,Croce F,Chou TC,Yang OO,Herrmann SH,Galli M,Hirsch MS

    更新日期：2000-09-01 00:00:00

  • Pre-incubation of cell-free HIV-1 group M isolates with non-nucleoside reverse transcriptase inhibitors blocks subsequent viral replication in co-cultures of dendritic cells and T cells.

    abstract：:In order to study the inhibitory effect of various reverse transcriptase inhibitors (RTIs) on cell-free HIV, we adapted a recently described in vitro system, based on co-cultures of dendritic cells and resting CD4 T cells, modelling early target cells during sexual transmission. The compounds tested included the secon...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Njai HF,Lewi PJ,Janssen CG,Garcia S,Fransen K,Kestens L,Vanham G,Janssen PA

    更新日期：2005-01-01 00:00:00

  • Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients.

    abstract：BACKGROUND:Pegylated interferon/ribavirin combination is currently the standard treatment for chronic hepatitis C virus (HCV) infection. Body weight adjustment of ribavirin is crucial for response. However, previous studies found no relation between ingested dose and plasma concentration. The aim of this study was to d...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Maynard M,Pradat P,Gagnieu MC,Souvignet C,Trepo C

    更新日期：2008-01-01 00:00:00

  • Activity of ergoferon against lethal influenza A (H3N2) virus infection in mice.

    abstract：BACKGROUND:The influenza A virus accounts for serious annual viral upper respiratory tract infections. It is constantly able to modify its antigenic structure, thus evading host defence mechanisms. Moreover, currently available anti-influenza agents have a rather limited application, emphasizing the further need for ne...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,收录出版

    doi：10.3851/IMP3115

    authors： Skarnovich MA,Emelyanova AG,Petrova NV,Borshcheva AA,Gorbunov EA,Mazurkov OY,Skarnovich MO,Tarasov SA,Shishkina LN,Epstein OI

    更新日期：2017-01-01 00:00:00

  • A light in the cognitive fog?

    abstract：:HIV escape in the central nervous system (CNS) despite undetectable viral load in the plasma has been observed and may contribute to HIV-associated neurocognitive disorders. Favouring the use of HIV drugs with a good penetration into the CNS has been advocated, leading to the establishment of the CNS penetration-effec...

    journal_title：Antiviral therapy

    pub_type： 评论,杂志文章

    doi：10.3851/IMP2561

    authors： Cavassini M,Du Pasquier RA

    更新日期：2013-01-01 00:00:00

  • Management of hepatitis B patients with antiviral resistance.

    abstract：:Drug resistance is an expected consequence of antiviral therapy for chronic hepatitis B because of the high rate of hepatitis B virus (HBV) replication, the lack of proof-reading during reverse transcription of the pregenomic RNA and the low efficacy of available therapies in eliminating covalently closed circular HBV...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：

    authors： Fung SK,Lok AS

    更新日期：2004-12-01 00:00:00

  • Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice.

    abstract：BACKGROUND:Virological success (VS) and immunological reconstitution (IR) of antiretroviral-naive HIV-1-infected patients with pre-therapy viral load (VL) >500,000 copies/ml was assessed after 12 months of treatment according to initial drug-class regimens. METHODS:An observational multicentre retrospective study was ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3197

    authors： Santoro MM,Di Carlo D,Armenia D,Zaccarelli M,Pinnetti C,Colafigli M,Prati F,Boschi A,Antoni AMD,Lagi F,Sighinolfi L,Gervasoni C,Andreoni M,Antinori A,Mussini C,Perno CF,Borghi V,Sterrantino G

    更新日期：2018-01-01 00:00:00

  • Automated nucleic acid isolation methods for HDV viral load quantification can lead to viral load underestimation.

    abstract：BACKGROUND:HDV infection is a cause of severe liver disease. Diagnosis and monitoring of HDV RNA are important to patient management. Since 2012, a WHO standard for HDV RNA quantification has been available; however, the impact of RNA extraction methods on HDV viral load quantification has never been evaluated. METHOD...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3281

    authors： Bremer B,Anastasiou OE,Ciesek S,Wedemeyer H

    更新日期：2019-01-01 00:00:00

  • Protective murine and human monoclonal antibodies against eczema vaccinatum.

    abstract：BACKGROUND:Eczema vaccinatum is the most common severe pathology associated with smallpox vaccination (vaccinia virus), occurring at high rates among individuals with a previous history of atopic dermatitis (atopic eczema). METHODS:Monoclonal antibodies capable of neutralizing vaccinia virus, anti-H3 and anti-B5, were...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP1717

    authors： Tomimori Y,Kawakami Y,McCausland MM,Ando T,Koriazova L,Kato S,Kawakami T,Crotty S

    更新日期：2011-01-01 00:00:00

  • Predicting antiretroviral drug resistance from the latest or the cumulative genotype.

    abstract：BACKGROUND:This study evaluates the added benefit when estimating antiretroviral drug resistance of combining all available resistance test results in a cumulative genotype relative to using the latest genotype alone. METHODS:The prevalence of resistance and genotypic sensitivity scores (GSS) predicted by the latest a...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP1753

    authors： Garcia F,Alvarez M,Fox Z,Garcia-Diaz A,Guillot V,Johnson M,Chueca N,Phillips A,Hernández-Quero J,Geretti AM

    更新日期：2011-01-01 00:00:00

  • Survival after long-term ART exposure: findings from an Asian patient population retained in care beyond 5 years on ART.

    abstract：BACKGROUND:This study investigated survival in people living with HIV being followed-up from 5 and 10 years after antiretroviral therapy (ART) initiation in a multi-country Asian cohort. METHODS:We included patients in follow-up >5 years after ART initiation. Factors associated with mortality beyond 5 and 10 years on ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3358

    authors： Bijker R,Kiertiburanakul S,Kumarasamy N,Pujari S,Sun LP,Ng OT,Lee MP,Choi JY,Nguyen KV,Chan YJ,Merati TP,Cuong DD,Ross J,Jiamsakul A,IeDEA Asia-Pacific.

    更新日期：2020-01-01 00:00:00

  • Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection.

    abstract：:There is a need for new antiretroviral drugs with activity against HIV isolates resistant to currently available agents and improved short and long-term tolerability profiles. Clinical trial designs for nucleotide and nucleoside reverse transcriptase inhibitors (NRTIs) are restricted by the characteristics of these ag...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：

    authors： Wainberg MA,Sawyer JP,Montaner JS,Murphy RL,Kuritzkes DR,Raffi F

    更新日期：2005-01-01 00:00:00

  • Early antiretroviral therapy: rationale, protease inhibitor-sparing regimens and once daily dosing.

    abstract：:In 1998 it seems reasonable and widely accepted that all human immunodeficiency virus type 1 (HIV-1)-infected patients willing to be treated may benefit from receiving antiretroviral therapy. Only those with undetectable plasma HIV-1 RNA, normal CD4 lymphocyte counts and lack of markers of immunological system activat...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：

    authors： Gatell JM

    更新日期：1998-01-01 00:00:00

  • Impact of tenofovir dose adjustment on both estimated glomerular filtration rate and tenofovir trough concentration.

    abstract：BACKGROUND:Tenofovir disoproxil fumarate (TDF)-based regimen is a treatment option for HIV-infected patients. TDF dose adjustment is recommended in patients with impaired renal function. We assessed the impact of TDF dose adjustment on renal function and tenofovir trough concentration. METHODS:Fourteen HIV patients fo...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3137

    authors： Bregigeon S,Solas C,Faucher O,Obry-Roguet V,Tamalet C,Poizot-Martin I

    更新日期：2017-01-01 00:00:00